Brian Stephenson
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Brian Stephenson
Brian Stephenson is recorded as CFO at BridgeBio Pharma, Inc. (BBIO) and CFO at Faeth Therapeutics, Inc. (FTH). Faeth Therapeutics, Inc. reported in an 8-K filed June 15, 2026 that Brian Stephenson was appointed Chief Financial Officer, effective June 13, 2026. The proxy statement of BridgeBio Pharma, Inc. reports total compensation of $684,661 for Brian Stephenson in fiscal 2025, including a base salary of $156,431. Disclosed compensation is on record for 8 fiscal years.
“Effective as of June 13, 2026, Brian Stephenson was appointed as the Company’s Chief Financial Officer and principal financial officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-06-13–present
-
Current
Start not stated–present
-
Start not stated–2025-03-17
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at BridgeBio Pharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Neil Kumar CEO, Board Member
- Charles Homcy Chairman, Board Member
- Thomas Trimarchi CFO, COO
- Brian Stolz COO
- Brian C. Stephenson Chief Accounting Officer
- Ali J. Satvat Board Member
- Andrea Ellis Board Member
- Andrea J. Ellis Board Member
- Andrew W. Lo Board Member
- Douglas A. Dachille Board Member
Leadership on record at Faeth Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Anand Parikh CEO, Chairman, COO, Board Member
- John Celebi CEO, Board Member
- William Ringo Chairman, Board Member
- Josiah Craver CFO, Chief Accounting Officer
- Christopher W. Gerry General Counsel, Board Member
- Bob Holmen Board Member
- Karen Vousden, Ph.D. Board Member
- Kristian Humer Board Member
- Phillip B. Donenberg Board Member
- Saira Ramasastry Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $156,431 | $684,661 |
| 2024 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $661,046 | $5,663,687 |
| 2023 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $650,000 | $6,651,996 |
| 2022 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Former Chief Financial Officer | $650,000 | $2,957,392 |
| 2021 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $600,000 | $8,677,297 |
| 2020 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $550,000 | $4,163,933 |
| 2019 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $420,000 | $4,198,967 |
| 2018 | BridgeBio Pharma, Inc. (BBIO) | Ph.D., CFA Chief Financial Officer | $74,375 | $2,347,115 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.